Drug Development

With the hire of Abecma veteran Dr. Steven Bernstein, Liberate Bio signals its readiness to take its 'off-the-shelf' CAR-M therapy into the clinic.

Promising early data for BBT001 suggests a potent combination of rapid relief and quarterly dosing, but can the biotech startup navigate the long road from pilot to production?

With its $2.2B acquisition of Forte, argenx adds a first-in-class antibody, FB102, expanding its Vision 2030 strategy to redefine autoimmune care.

A positive EMA opinion for Minoryx's NEZGLYAL offers the first-ever drug therapy for a fatal childhood disease, highlighting a key regulatory pathway.

Radiopharm Theranostics secures crucial funding for its promising oncology pipeline, but a sharp stock drop reveals deep investor concerns about dilution.

Samsung Epis Holdings reports solid growth driven by its biosimilar portfolio, but the real story is its strategic pivot to next-gen cancer drugs and global expansion.

Ipsen's BOLD trial for biliary atresia failed, a blow to families. But in the data from this setback lies a critical roadmap for future research.

Taiwan's Jyong Biotech touts a global licensing strategy for its BPH drug, but a closer look reveals significant clinical setbacks and financial pressures.

A Korean biotech is betting big on the U.S. market with its new GERD drug. A deal with manufacturer Bora Pharmaceuticals is the first step. Is it enough?

With a billion people globally struggling with sleep apnea and CPAP compliance low, Incannex Healthcare is advancing its oral drug IHL-42X, now in a key Phase 2 study.

Bio-Thera Solutions has begun a Phase 1 trial for BAT8013, a novel ADC targeting CD25 to deplete immunosuppressive cells in the tumor microenvironment.

With key hires in finance, regulatory, and manufacturing, Cyllene Therapeutics signals it's preparing for the big leagues. But can it deliver?

A scientific breakthrough reveals a reversible cause for sarcopenia, offering the first real hope for a drug therapy to restore strength for millions of seniors.

A new clinical trial combines two targeted therapies, offering potential hope for kidney cancer patients who have exhausted even the newest treatment options.

A new publication on Oncotelic's Sapu003 isn't just science; it's a critical de-risking event validating a manufacturing and drug delivery platform.

Flatiron Health's landmark partnership with Scotland's NHS signals a new era where localized, real-world data becomes a critical asset in the global race for cancer cures.

Acclaimed scientist Michael Ehlers leaves big pharma's orbit for an AI startup. It's more than a career move; it's a test of whether technology can fix our broken drug development system.

SKNV's exclusive deal for a university-developed therapy shortens precancerous skin treatment to just four days, challenging norms in both patient care and pharmaceutical commercialization.

A new partnership between Evogene and ELEO leverages AI and natural product science to create an oral PCSK9 inhibitor, aiming to disrupt a $23B market.